Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Alemtuzumab increases the likelihood of disability improvement in MS

Key clinical point: More than one-third of patients achieved 6-month confirmed disability improvement over 6 years.

Major finding: Patients with baseline EDSS scores between 4.0 and 4.5 are most likely to achieve disability improvement.

Study details: An analysis of pooled data for 565 patients in the CARE-MS I and CARE-MS II studies.

Disclosures: Sanofi, Bayer HealthCare Pharmaceuticals supported the study.

Citation:

Hunter SF et al. CMSC 2019. Abstract DXT08.